BioSpace News Archive

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personaliz

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and con

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of its first patient in GRADIENT, a double-blind, placebo-controlled, Phase 3 trial of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas or hyperplasia. “We are

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales.

Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, announced today that it will release second quarter 2020 results after the market close on Tuesday, August 11, 2020.

Thermo Scientific Gemini Analyzer with LowDoseID for narcotics analysis eliminates concentration limitations from testing process

The Centers for Disease Control and Prevention (CDC) and healthcare professionals have expressed alarm that hospitals may not have the capacity to handle the avalanche of influenza (flu) patients in addition to COVID-19 patients as we enter flu season.

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2020 conference call on Wednesday, August 5, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grants of equity awards to purchase a total of 155,000 shares of common stock to three

Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) SAN FRANCISCO--( BUSINESS WIRE )-- Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in oncology, announced today that the first patient has been dosed with CB-5339 in a Phase 1 clinical tr